Page 6 - அறுவை சிகிச்சை புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Imugene collaborator wins FDA Investigational New Drug approval to initiate CHECKvacc phase one trial Imugene managing director and chief executive officer Leslie Chong called the approval a “major milestone” for the company as it prepares to commence a phase one trial into metastatic, triple-negative breast cancer with its CHECKvacc drug candidate. Imugene is a step closer to trialling its oncolytic virotherapy candidate in a phase one study on patients with triple-negative breast cancer. Imugene Limited’s (ASX:IMU) (OTCMKTS:IUGNF) has achieved a major milestone with US collaborator City of Hope® securing Investigational New Drug (IND) approval for an upcoming phase one trial of the ASX-lister’s oncolytic virotherapy candidate.

Leslie chongImugene checkvaccLos angelesYuman fongA phasei study of intratumoral administrationDrug administrationImugene limitedInvestigational new drugPhasei studyIntratumoral administrationMetastatic triple negative breastProfessor yumanSangiacomo family chairSurgical oncologyலெஸ்லி சோங்லாஸ் ஏஞ்சல்ஸ்